Cargando…

Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study

BACKGROUND: Type 2 diabetes mellitus is associated strongly with an increased risk of micro- and macro-vascular complications, leading to impaired quality of life and shortened life expectancy. In addition to appropriate glycemic control, multi-factorial intervention for a wide range of risk factors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Atsushi, Murohara, Toyoaki, Taguchi, Isao, Eguchi, Kazuo, Suzuki, Makoto, Kitakaze, Masafumi, Sato, Yasunori, Ishizu, Tomoko, Higashi, Yukihito, Yamada, Hirotsugu, Nanasato, Mamoru, Shimabukuro, Michio, Teragawa, Hiroki, Ueda, Shinichiro, Kodera, Satoshi, Matsuhisa, Munehide, Kadokami, Toshiaki, Kario, Kazuomi, Nishio, Yoshihiko, Inoue, Teruo, Maemura, Koji, Oyama, Jun-ichi, Ohishi, Mitsuru, Sata, Masataka, Tomiyama, Hirofumi, Node, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020545/ https://www.ncbi.nlm.nih.gov/pubmed/27619983 http://dx.doi.org/10.1186/s12933-016-0449-7

Ejemplares similares

Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial
por: Oyama, Jun-ichi, et al.
Publicado: (2016)

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study
por: Tomiyama, Hirofumi, et al.
Publicado: (2016)

Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study
por: Oyama, Jun-ichi, et al.
Publicado: (2016)

Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study
por: Kishimoto, Shinji, et al.
Publicado: (2023)

Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study
por: Yamada, Hirotsugu, et al.
Publicado: (2017)

Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study
por: Maruhashi, Tatsuya, et al.
Publicado: (2016)

Factors associated with carotid intima-media thickness progression in patients with asymptomatic hyperuricemia: insights from the PRIZE study
por: Saito, Yuichi, et al.
Publicado: (2023)

Reduced reactive hyperemia of the brachial artery in diabetic patients assessed by repeated measurements: The FMD‐J B study
por: Masaki, Nobuyuki, et al.
Publicado: (2023)

Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study
por: Kusunose, Kenya, et al.
Publicado: (2021)

Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Brachial‐Ankle Pulse Wave Velocity Versus Its Stiffness Index β‐Transformed Value as Risk Marker for Cardiovascular Disease
por: Tomiyama, Hirofumi, et al.
Publicado: (2019)

Effect of febuxostat on the level of malondialdehyde‐modified low‐density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study
por: Teragawa, Hiroki, et al.
Publicado: (2023)

Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study
por: Maruhashi, Tatsuya, et al.
Publicado: (2022)

Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse
por: Salim, Hotimah Masdan, et al.
Publicado: (2016)

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial
por: Tanaka, Atsushi, et al.
Publicado: (2016)

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014)

Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
por: Tanaka, Atsushi, et al.
Publicado: (2023)

Diagnostic Criteria of Flow‐Mediated Vasodilation for Normal Endothelial Function and Nitroglycerin‐Induced Vasodilation for Normal Vascular Smooth Muscle Function of the Brachial Artery
por: Maruhashi, Tatsuya, et al.
Publicado: (2020)

Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial
por: Sezai, Akira, et al.
Publicado: (2022)

Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Do incretins improve endothelial function?
por: Oyama, Jun-ichi, et al.
Publicado: (2014)

Endothelial Dysfunction, Increased Arterial Stiffness, and Cardiovascular Risk Prediction in Patients With Coronary Artery Disease: FMD‐J (Flow‐Mediated Dilation Japan) Study A
por: Maruhashi, Tatsuya, et al.
Publicado: (2018)

Fluctuation of Blood Pressure in a Patient With Pheochromocytoma
por: Fujii, Yuichi, et al.
Publicado: (2020)

New risk factors of severe hypoglycemia
por: Matsuhisa, Munehide, et al.
Publicado: (2018)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Ipragliflozin/tozinameran: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Association of accumulated advanced glycation end‐products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes
por: Mori, Hiroyasu, et al.
Publicado: (2019)

Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial
por: Kusunose, Kenya, et al.
Publicado: (2021)

Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
por: Kamezaki, Michitsugu, et al.
Publicado: (2018)

A concise and practical stereoselective synthesis of ipragliflozin L-proline
por: Ma, Shuai, et al.
Publicado: (2017)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
por: van Kleef, Laurens A., et al.
Publicado: (2022)

Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan
por: Kadowaki, Takashi, et al.
Publicado: (2022)

Rationale and design of a multicenter randomized study comparing the efficacy and safety of esaxerenone versus trichlormethiazide in patients with uncontrolled essential hypertension: EXCITE‐HT study
por: Kario, Kazuomi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rvs8com0fc4gb282e37u2drfuv